Regeneron vs. Omicron; The Fed’s New Plan; The Boss’ Half-a-Billion

Regeneron Pharmaceuticals is developing new antibodies that work against the omicron variant of Covid-19, after the company confirmed that its current cocktail has diminished potency against the heavily mutated strain. CEO Leonard Schleifer says Regeneron plans to conduct trials on the new antibodies in the first quarter of 2022.  The Federal Reserve’s move to accelerate its taper but not yet move the needle on interest rates has left market analysts in disagreement over whether it was the right call and how it could impact stocks. CNBC’s Steve Liesman breaks down how the markets are reacting to the Federal Reserve’s policy pivot on Wednesday. Plus, Bruce Springsteen has reportedly sold his music rights to Sony Music Entertainment in what could be the biggest deal ever struck for a single artist’s work.In this episode:Leonard Schleifer, @RegeneronMeg Tirrell, @megtirrell Steve Liesman, @steveliesmanJoe Kernen, @JoeSquawkBecky Quick, @BeckyQuickAndrew Ross Sorkin, @andrewrsorkinKlaire Odumody, @klairemarie Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.